Palonosetron is a highly potent second-generation 5-HT3 receptor antagonist utilized in the management and prevention of chemotherapy-induced nausea and vomiting (CINV). It is commercially accessible under the brand name Aloxi. Notably, Palonosetron is unique in its prolonged half-life and its strong binding affinity to 5-HT3 receptors. Unlike other drugs in its class, Palonosetron can be administered either intravenously or orally as a single capsule. It inhibits the actions of serotonin, a substance that could trigger nausea and vomiting. Its primary pharmacological function is selectively antagonizing the serotonin 5-HT3 receptors located in the central nervous system and gastrointestinal tract.
![N-[(S)-1-Azabicyclo[2,2,2]oct-3-yl]-5,6,7,8-tetrahydro-1-naphthelene carboxamide](https://veeprho.com/wp-content/uploads/2022/07/N-5BS-1-Azabicyclo5B2-2-25Doct-3-yl5D-5-6-7-8-tetrahydro-1-naphthelene-carboxamide.png "N-[(S)-1-Azabicyclo[2,2,2]oct-3-yl]-5,6,7,8-tetrahydro-1-naphthelene carboxamide")
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Parent: Palonosetron
Palonosetron related compounds comprise of various impurities that might form over the course of its lifecycle. These impurities or degradants could emerge during synthesis, storage, or even upon administration. They might include residues of starting materials, by-products, intermediates, degradants, and other potential impurities. However, it’s important to note that the total impurities of Palonosetron are controlled within acceptable limits to ensure the drug’s safety and efficacy as per the regulators’ guidelines.
While both ondansetron and palonosetron are 5-HT3 receptor antagonists and function to reduce nausea and vomiting, their main difference lies in their chemical structures and pharmacokinetic properties. Palonosetron is a second-generation 5-HT3 antagonist with a significantly longer half-life and a higher binding affinity than ondansetron, which makes it effective in preventing both acute and delayed CINV.
Both Aloxi (palonosetron) and Zofran (ondansetron) are effective in reducing nausea and vomiting induced by chemotherapy. However, Aloxi is generally considered more effective due to its prolonged half-life and strong receptor binding affinity, especially in preventing delayed CINV.
Palonosetron has a longer mechanism of action compared to other 5-HT3 antagonists. It’s known for its extensive half-life, lasting up to 40 hours. This makes it extremely effective in preventing both acute and delayed chemotherapy-induced nausea and vomiting.
No, Palonosetron is not a steroid. It’s a second-generation 5-HT3 receptor antagonist used primarily to prevent nausea and vomiting induced by chemotherapy. It works by blocking the activity of serotonin, a natural substance in the body known to trigger these symptoms.
